Paul A Fitzpatrick

US Patent:

6441135, Aug 27, 2002

Filed:

Feb 11, 2000

Appl. No.:

09/381488

Inventors:

Michael C. Kiefer - Clayton CA
Paul A. Fitzpatrick - Albany CA
Helen L. Gibson - Oakland CA
Philip J. Barr - Oakland CA

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C07K 100

US Classification:

530350, 530300, 435 71, 435 691, 536 231

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention neither provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the âBBP Binding Domainsâ and the respective nucleotides, designated âbbpbd-1â and âbbpbd-2â which arc involved in the interaction between Bak and BBP.

US Patent:

7316915, Jan 8, 2008

Filed:

Jul 1, 2002

Appl. No.:

10/189294

Inventors:

Michael C. Kiefer - Clayton CA, US
Paul A. Fitzpatrick - Albany CA, US
Helen L. Gibson - Oakland CA, US
Philip J. Barr - Oakland CA, US

Assignee:

Tanox, Inc. - Houston TX

International Classification:

C12P 21/06

US Classification:

435 691, 435 6, 435 71, 530350

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.

US Patent:

7888038, Feb 15, 2011

Filed:

Oct 9, 2006

Appl. No.:

11/539859

Inventors:

Michael C. Kiefer - Clayton CA, US
Paul A. Fitzpatrick - Albany CA, US
Helen L. Gibson - Oakland CA, US
Philip J. Barr - Oakland CA, US

Assignee:

Genetech, Inc. - South San Francisco CA

International Classification:

G01N 33/53

US Classification:

435 71, 4353201, 435252, 435325, 435 691, 530350

Abstract:

The present invention provide polynucleotide sequences encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provide recombinant host cells containing polynucleotides encoding BBP. The invention further provide antibodies that specifically bind to BBP. The invention further provide methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provide methods for detecting the presence of Bak polynucleotides and the encoding proteins in a biological sample, and further provide methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.

US Patent:

20120142099, Jun 7, 2012

Filed:

Jan 19, 2011

Appl. No.:

13/009228

Inventors:

Michael C. Kiefer - Clayton CA, US
Paul A. Fitzpatrick - Albany CA, US
Helen L. Gibson - Oakland CA, US
Philip J. Barr - Oakland CA, US

Assignee:

GENENTECH, INC. - South San Francisco CA

International Classification:

C12N 5/02

US Classification:

435375

Abstract:

The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.

US Patent:

20130039898, Feb 14, 2013

Filed:

Feb 3, 2011

Appl. No.:

13/576625

Inventors:

Augustus O. Okhamafe - Concord CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - Novato CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - NOVATO CA

International Classification:

A61K 38/51
A61P 3/00
A61P 7/00
C12N 9/88

US Classification:

424 945, 435232

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.